The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis

By T. Staa, H. Leufkens, Chris Cooper. Osteoporosis International, 2002

1,283 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A Meta‐Analysis of Prior Corticosteroid Use and Fracture Risk (2004, background): “The risk for vertebral fracture may be somewhat higher.((3)) The largest and most recent study examined fracture risk in the general practice research data base of the United Kingdom,((4)) where 250,000 corticosteroid users were compared with ageand sex-matched controls.”
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy (2013, background): “and an increase in fracture risk within 3 to 6 months of treatment initiation; this increased fracture risk was independent of patient age, gender and the underlying disease [14].”
Glucocorticoid-induced osteoporosis: pathophysiology and therapy (2007, background): “They occur more frequently in postmenopausal women and men at sites enriched in cancellous bone, such as the vertebrae and femoral neck [64, 65].”
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. (2010, background): “5 mg/d of prednisone or its equivalent increases the risk of gonadotropin and testosterone suppression and alterations in muscle and bone mass (149).”
Assessment of fracture risk (2005, background): “Table 7 Meta-analysis of the risk of fracture in women with a prior fracture at the sites shown (adapted from [43])”